Correlation Engine 2.0
Clear Search sequence regions


  • anthracyclines (7)
  • cellular (1)
  • heart failure (2)
  • help (1)
  • humans (1)
  • patients (2)
  • therapies (1)
  • Sizes of these terms reflect their relevance to your search.

    Anthracyclines (ANTs) are powerful drugs that have reduced the mortality of cancer patients. However, their use is limited by the development of cardiotoxicity (CTX), which is dose dependent and may lead to left ventricular dysfunction and heart failure. Although various strategies have been suggested to reduce the negative effects of ANTs, CTX is still an important unresolved clinical issue. This may be due at least partly to the incomplete characterization of the molecular and cellular mechanisms of ANT-induced CTX. In addition, although various forms of cardiac damage have been demonstrated with the use of these drugs in experimental studies, it is not yet clear how these translate to the clinical setting. Appropriate characterization of potential candidates for ANT-based therapies is essential to decide whether to administer these drugs. Hopefully, new information from genetic profiling will help to identify patients who are at high risk of developing CTX.

    Citation

    Donato Mele, Carlo G Tocchetti, Pasquale Pagliaro, Rosalinda Madonna, Giuseppina Novo, Alessia Pepe, Concetta Zito, Nicola Maurea, Paolo Spallarossa. Pathophysiology of anthracycline cardiotoxicity. Journal of cardiovascular medicine (Hagerstown, Md.). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e3-e11

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 27755237

    View Full Text